A detailed history of Vanguard Group Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 4,740,171 shares of AVXL stock, worth $40.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,740,171
Previous 4,548,219 4.22%
Holding current value
$40.9 Million
Previous $19.2 Million 40.28%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.11 - $7.04 $788,922 - $1.35 Million
191,952 Added 4.22%
4,740,171 $26.9 Million
Q2 2024

Aug 13, 2024

BUY
$3.39 - $5.02 $452,690 - $670,355
133,537 Added 3.02%
4,548,219 $19.2 Million
Q1 2024

May 10, 2024

BUY
$4.55 - $6.75 $245,854 - $364,729
54,034 Added 1.24%
4,414,682 $22.5 Million
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $581,132 - $1.15 Million
115,304 Added 2.72%
4,360,648 $40.6 Million
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $269,814 - $385,978
41,193 Added 0.98%
4,245,344 $27.8 Million
Q2 2023

Aug 14, 2023

BUY
$7.66 - $9.5 $256,970 - $318,696
33,547 Added 0.8%
4,204,151 $34.2 Million
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $217,185 - $306,722
26,104 Added 0.63%
4,170,604 $35.7 Million
Q4 2022

Feb 10, 2023

BUY
$7.65 - $14.43 $294,563 - $555,627
38,505 Added 0.94%
4,144,500 $38.4 Million
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $1.07 Million - $1.54 Million
119,684 Added 3.0%
4,105,995 $42.4 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $744,669 - $1.31 Million
101,870 Added 2.62%
3,986,311 $39.9 Million
Q1 2022

May 13, 2022

BUY
$9.74 - $17.69 $417,563 - $758,387
42,871 Added 1.12%
3,884,441 $47.8 Million
Q4 2021

Feb 14, 2022

SELL
$16.88 - $23.31 $2.53 Million - $3.49 Million
-149,802 Reduced 3.75%
3,841,570 $66.6 Million
Q3 2021

Nov 12, 2021

BUY
$16.82 - $25.75 $5.78 Million - $8.84 Million
343,379 Added 9.41%
3,991,372 $71.6 Million
Q2 2021

Aug 13, 2021

BUY
$10.16 - $28.86 $37.1 Million - $105 Million
3,647,993 New
3,647,993 $83.4 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.